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Abstract
Background: Atrial fibrillation (AF) is a common supraventricular arrhythmia more
frequently observed in large breed dogs.
Objectives: Estimate the prevalence of AF in dogs with myxomatous mitral valve dis-
ease (MMVD) and identify risk factors for developing AF.
Animals: A total of 2194 client-owned dogs with MMVD, including 1280, 588, 290,
and 36 dogs in ACVIM stages B1, B2, C, and D, respectively.
Methods: Retrospective, cross-sectional study. The medical databases of 3 veterinary
teaching hospitals were reviewed. Inclusion criteria were a diagnosis of MMVD after
complete cardiovascular evaluation and cardiac rhythm assessment using routine
2-minute ECG or good quality ECG tracing during echocardiographic examination.
Results: Atrial fibrillation was diagnosed in 59 dogs with a prevalence of 2.7%. Uni-
variate analysis showed that mixed breed, male sex, advanced ACVIM stage, left atrial
and ventricular enlargement, fractional shortening (FS), and presence of pulmonary
hypertension were significantly associated with development of AF. According to
2 multivariable models, the left atrium (LA)-to-aorta ratio (odds ratio [OR] = 14.011,
7.463-26.304), early trans-mitral velocity (OR = 2.204, 1.192-4.076), body weight
(OR = 1.094, 1.058-1.130), and FS (OR = 0.899, 0.865-0.934) and LA (OR = 5.28,
3.377-8.092), advanced ACVIM stage (OR = 4.922, 1.481-16.353), and FS
(OR = 0.919, 0.881-0.959) were significant predictors of AF for models 1 and
2, respectively.
Conclusions and Clinical Importance: Atrial fibrillation is an uncommon complication
of MMVD and is significantly associated with the more advanced stage of the dis-
ease, increased LA dimension and body weight, and decreased FS.
Abbreviations: 2D, 2-dimensional; ACVIM, American College of Veterinary Internal Medicine; AF, atrial fibrillation; Ao, aortic root diameter; AUC, area under the curve; BW, body weight; CI,
confidence interval; CT, cardiac treatment; E max, mitral valve maximal E wave velocity; FS, fractional shortening; HF, heart failure; LA, left atrial diameter; LA/Ao, left atrium to aorta ratio; LAE,
left atrial enlargement; LV, left ventricle; LVDD, left ventricular diastolic diameter; LVDDn, left ventricular diastolic diameter normalized for body weight; LVSD, left ventricular systolic diameter;
LVSDn, left ventricular systolic diameter normalized for body weight; MMVD, myxomatous mitral valve disease; MT, mixed treatment; NPV, negative predictive value; NT, no treatment; OR,
odds ratio; OT, other treatments; PH, pulmonary hypertension; PPV, positive predictive value; ROC, receiver operating characteristic; TR, tricuspid regurgitation; VTH, veterinary teaching
hospital.
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1 | INTRODUCTION
Atrial fibrillation (AF) is the most common supraventricular arrhythmia
in both humans and dogs.1-4 Although some dogs can develop AF in
the absence of recognizable cardiac disease (ie, primary or lone AF),
AF secondary to cardiac diseases associated with left atrial enlarge-
ment (LAE) is more commonly observed.3,4 In humans, the prevalence
and risk factors associated with development of AF are well
known.1,2,5-7 In particular, heart failure (HF) and AF are linked by simi-
lar risk factors in people and share a common pathophysiology.1,2,5-7
Thus, it is widely accepted that HF and AF can cause and exacerbate
each other through mechanisms such as structural cardiac remodeling,
activation of neuro-hormonal mechanisms, and rate-related impair-
ment of left ventricular function.1,2,5-7
In dogs, AF usually is observed in animals with dilated cardiomy-
opathy, myxomatous mitral valve disease (MMVD), or congenital car-
diac disease associated with LAE.3,4 Among these diseases, MMVD is
the most frequently diagnosed, accounting for approximately 70% of
acquired cardiac disease in dogs.8-10 Progressive LAE is a common
sequela during MMVD progression, and guidelines provided by the
American College of Veterinary Internal Medicine (ACVIM)
established a specific classification scheme of the different stages of
HF associated with MMVD.9,10 Although some epidemiologic data
and associations for AF development have been described in dogs,3,11
no study has thoroughly examined the prevalence rate and risk factors
for this arrhythmia in dogs with MMVD. In addition, results of a
recent study showed that the presence of AF is associated with a
worse prognosis in medium to large-sized dogs with MMVD.12 Thus,
knowledge of the risk factors for developing AF is useful in the clinical
evaluation of dogs with MMVD.
We estimated the prevalence of AF in a large population of dogs
with MMVD and identified the risk factors for developing AF in these
animals. We hypothesized that AF is associated with worsening of
MMVD and that some clinical variables and echocardiographic param-
eters indicative of cardiac remodeling can be useful predictors of
developing AF in dogs with MMVD.
2 | MATERIAL AND METHODS
2.1 | Animals
For this retrospective study, data were collected from the internal
database of the veterinary teaching hospitals (VTH) of the Universities
of Padova, Bologna, and Curitiba. Dogs were recruited to the study
from those undergoing cardiac diagnostic evaluation and final diagno-
sis of MMVD between January 2012 and December 2018. Diagnosis
of MMVD was based on clinical and echocardiographic findings
including a left apical systolic murmur, thickened or prolapsing mitral
valve leaflets or both on 2-dimensional (2D) echocardiography associ-
ated with mitral valve regurgitation on color flow Doppler interroga-
tion.9,10 Disease severity was classified according to the ACVIM
guidelines.9,10 The presence or absence of AF was based on at least
1 of the following methods: routine surface ECG recording with dedi-
cated machines of at least 2 minutes duration or good quality ECG
recordings during the echocardiographic examination. In particular,
the echocardiographic diagnosis of AF was based on the combined
presence of the following findings: irregularly irregular cardiac rhythm
with narrow QRS complexes, isoelectric trace without recognizable P
waves, and absence of A wave on mitral inflow on Doppler
interrogation.
For dogs with more visits available during the period of observa-
tion, only data obtained during the most recent visit and those
obtained during the first visit documenting AF were analyzed for dogs
without AF and those developing AF, respectively. Dogs with sinus
rhythm and dogs with cardiac arrhythmias other than AF were merged
together and only 2 groups were considered for analysis: dogs with
AF and dogs without AF. The absence of a final rhythm diagnosis was
considered an exclusion criterion. Dogs with equivocal cardiac diagno-
sis or other concomitant congenital or acquired cardiac disease also
were excluded from this study.
2.2 | Echocardiographic examination
At each VTH, an experienced operator performed the echocardio-
graphic examination. The left ventricular diameter at diastole (LVDD)
and systole (LVSD) were measured from M-mode short-axis echocar-
diographic images at the level of the chordae tendinae and fractional
shortening (FS) then was calculated according to the formula (LVDD-
LVSD)/LVDD. Normalized left ventricular (LV) dimensions (ie, LVDSn
and LVDDn) were calculated according to reported allometric scaling.13
Left atrial diameter (LA) and aortic root diameter (Ao) were measured at
early diastole from 2D echocardiographic short axis images obtained at
the level of the heart base and the LA/Ao ratio then was calcu-
lated.14,15 Pulsed-wave Doppler interrogation of trans-mitral blood flow
was obtained from the left apical 4-chamber view and the peak of the
early diastolic wave (E max) was measured. Multiple views were used
to evaluate trans-tricuspid blood flow and the maximal value of any tri-
cuspid regurgitation (TR) velocity was measured using continuous-wave
Doppler. In the absence of right ventricular outflow obstruction, the
presence of pulmonary hypertension (PH) was considered when the TR
maximal velocity was ≥3 m/s, corresponding to a Doppler-derived esti-
mated systolic pressure gradient of 36 mm Hg.16
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2.3 | Statistical analysis
Data were entered into an electronic spreadsheet (Microsoft Excel,
Microsoft Office 2011, Microsoft Corporation, Bellevue, Washington).
Statistical analyses were carried out using commercially available soft-
ware (IBM Corp. Released 2016. IBM SPSS Statistics for Windows,
Version 24.0. Armonk, New York: IBM Corp.; MedCalc Statistical
Software version 16.4.3, MedCalc Software, Ostend, Belgium). Data
obtained from the case records were: sex, breed, age, body weight
(BW), ongoing treatment at the time of examination, and ACVIM class.
For breed, ACVIM class, and ongoing treatment, the following binary
or quaternary categories were considered, respectively: purebred and
crossbred; dogs with compensated MMVD (ie, dogs with MMVD but
without past or current development of HF, corresponding to ACVIM
classes B1 and B2) and dogs with decompensated MMVD (ie, dogs
with MMVD with past or current evidence of HF, corresponding to
ACVIM classes C and D)9,10; dogs receiving no treatment (NT), any
treatment for cardiac disease (CT), any other treatment for noncardiac
disease (OT), and mixed treatment (MT) for concurrent cardiac and
noncardiac disease, at time of enrollment. The following continuous
echocardiographic variables were considered: LA, LA/Ao, LVDDn,
LVSDn, FS, and E max. Furthermore, LA/Ao ≥ 1.6, LVDDn ≥ 1.7,
LVSDn ≥ 1.2, FS ≥ 40%, E max ≥ 1.2 m/s, and TR velocity ≥ 3 m/s
were used to create the binary variables classifying dogs with or with-
out LAE, LV diastolic and systolic enlargement, hyperdynamic LV,
increased LA pressure, and PH, respectively.10,13-17
Continuous data were assessed graphically for normality and pres-
ented as mean and SD, whereas categorical variables are presented as
number and percentage within each category. Comparison of clinical
and echocardiographic variables between dogs with MMVD developing
AF and those not developing AF was carried out using the Student's
t test and the Fisher's exact test or the Chi-square test with Yate's cor-
rection for continuous and categorical variables, respectively.
Ability to distinguish between dogs developing AF and those not
developing AF of the main continuous variables showing a significant dif-
ference between dogs with and without AF (ie, BW, LA, LA/Ao, LVDDn,
TABLE 1 Descriptive data obtained from 2194 dogs with myxomatous mitral valve disease with and without atrial fibrillation (AF)
Variable Category
AF group, n = 59 dogs No AF group, n = 2135 dogs
P valueNumber (%), mean ± SD Missing values, n (%) Number (%), mean ± SD Missing values, n (%)
Breed Crossbred 35 (59.3) 817 (38.3) .002
Purebred 24 (40.7) 1318 (61.7)
Age (mo.) mean ± SD 136 ± 28 136 ± 35 27 (1.3) .69
Sex Female 18 (30.5) 1141 (53.5) 3 (0.1) .001
Male 41 (69.5) 991 (46.5)
BW (kg) Mean ± SD 17.3 ± 10.6 10.7 ± 8.6 11 (0.5) <.001
HR (bpm) Mean ± SD 187 ± 41 1 (1.7) 128 ± 31 5 (0.2) <.001
LA (cm) Mean ± SD 4.98 ± 0.97 1 (1.7) 2.38 ± 0.80 2 (0.1) <.001
Ao (cm) Mean ± SD 1.91 ± 0.48 1 (1.7) 1.60 ± 0.43 2 (0.1) <.001
LA/Ao Mean ± SD 2.72 ± 0.67 1 (1.7) 1.52 ± 0.47 2 (0.1) <.001
LVDDn Mean ± SD 2.06 ± 0.36 1.55 ± 0.32 20 (0.9) <.001
LVSDn Mean ± SD 1.26 ± 0.28 0.85 ± 0.23 22 (1.0) <.001
FS (%) Mean ± SD 36.9 ± 10.4 43.5 ± 9.6 11 (0.5) <.001
E max (m/s) Mean ± SD 1.49 ± 0.37 3 (5.1) 0.83 ± 0.36 19 (0.9) <.001
PH No 31 (52.5) 1638 (76.7) <.001
Yes 28 (47.5) 497 (23.3)
ACVIM stage B1 + B2 6 (10.2) 1861 (87.2) <.001
C + D 53 (89.8) 274 (12.8)
Treatment CT/NT 48 (84.8)/9 (15.8) 263 (14.0)/1619 (86.0) <.001
CT/MT 48 (100.0)/0 (0.0) 263 (84.8)/47 (15.2) .007
CT/OT 48 (96.0)/2 (4.0) 263 (56.1)/206 (43.9) <.001
MT/OT 0 (0.0)/2 (100.0) 47 (18.6)/206 (81.4) .81
MT/NT 0 (0.0)/9 (100.0) 47 (2.8)/1619 (97.2) .62
NT/OT 11 (84.6)/2 (15.4) 206 (11.3)/1619 (88.7) .81
Abbreviations: ACVIM, American College of Veterinary Internal Medicine; AF, atrial fibrillation; BW, body weight; CT, cardiac treatment; E max, mitral valve
maximal E wave velocity; FS, fractional shortening; HR, heart rate; LA, left atrial diameter; LA/Ao, left atrial diameter to aortic diameter; LVDDn, left ven-
tricular diastolic diameter normalized to body weight; LVSDn, left ventricular systolic diameter normalized to body weight; MT, mixed treatment; n, number
of dogs; NT, no treatment; OT, other treatments; PH, pulmonary hypertension.
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LVSDn, FS, and E max) was evaluated by receiver operating characteris-
tic (ROC) curve analysis. The corresponding area under the curve (AUC)
with binomial exact confidence interval (CI) was calculated successively.
In particular, the sensitivity, specificity, and negative (NPV) and positive
predictive values (PPV) were calculated at various cut-off points.
Univariate and multivariable logistic regression analysis estimated
the odds ratio (OR) with 95% CI of developing AF. In particular, the
following variables were analyzed as dichotomous variables and
assessed in the univariate analysis: breed (crossbred vs purebred), sex
(female vs male), BW (≤20 kg vs >20 kg), LA (<3.45 cm vs ≥3.45 cm),
LA/Ao (<1.6 vs ≥1.6), LVDDn (<1.7 vs ≥1.7), LVSDn (<1.2 vs ≥1.2), FS
(<40% vs ≥40%), E-max (<1.2 m/s vs ≥1.2 m/s), PH (yes vs no), treat-
ment (OT vs CT + MT + NT), and ACVIM stage (B1 + B2 vs C + D).
Two multivariable models then were built using variables significantly
associated with AF in the univariate analysis after evaluation of auto-
correlation and interaction between predictors. After applying the
stepwise backward elimination method, model 1 included BW and the
echocardiographic predictors LA/Ao, E-max, and FS as continuous
variables, and model 2 included the echocardiographic predictors LA
and FS as continuous variables, and ACVIM stage as a dichotomous
categorical variable. The Exp(B) was calculated and reported as OR
with 95% CI for each incremental unit or for the level of interest of
the continuous variables and the categorical variable, respectively.
A value of P < .05 was considered significant.
3 | RESULTS
3.1 | Study population and echocardiographic
parameters
A total of 2194 dogs with MMVD were recruited in the study, includ-
ing 1280, 588, 290, and 36 dogs in the ACVIM stages B1, B2, C,
and D, respectively. Pulmonary hypertension was diagnosed in
526 dogs (23.9%). At enrollment, 1628 dogs (74.2%) were receiving
NT; 311 dogs (14.2%) ≥1 drugs for cardiac disease; 47 dogs ≥1 drugs
for both cardiac disease and concomitant noncardiac disease (2.1%);
and 208 dogs (9.5%) ≥1 drugs only for concomitant noncardiac
TABLE 2 Diagnostic accuracy of 7 clinical and echocardiographic variables to predict developing of atrial fibrillation in 2194 dogs with
myxomatous mitral valve disease
Variable AUC 95% CI Cut-off Sensitivity (%) Specificity (%) PPV (%) NPV (%)
BW (kg) 0.735 0.716-0.754 7.6 96.6 44.4 4.6 99.8
LA (cm) 0.979 0.972-0.984 >3.45 98.3 89.8 20.7 99.9
LA/Ao 0.931 0.920-0.941 >1.8 98.3 78.5 11.0 99.9
LVDDn 0.854 0.796-0.912 >1.82 81.4 82.2 10.1 99.4
LVSDn 0.875 0.821-0.929 >1.08 79.7 86.7 14.4 99.3
FS (%) 0.682 0.662-0.702 ≤40.1 70.7 60.1 4.7 98.7
E max (m/s) 0.900 0.887-0.912 >1.02 91.1 79.0 10.3 99.7
Abbreviations: AUC, area under the curve; BW, body weight; CI, confidence interval; E max, mitral valve maximal E wave velocity; FS, fractional shortening;
LA, left atrial diameter; LA/Ao, left atrial diameter to aortic diameter; LVDDn, left ventricular diastolic diameter normalized to body weight; LVSDn, left
ventricular systolic diameter normalized to body weight; NPV, negative predictive value; PPV, positive predictive value.
TABLE 3 Results of the univariate logistic regression analysis
showing the association between the risks for developing atrial
fibrillation in 2194 dogs with myxomatous mitral valve disease
Variable Category Odds ratio (95% CI) P value
Breed Crossbred 0.425 (0.251-0.720) .002
Purebred
Sex Female 2.623 (1.497-4.594) .001
Male
BW (kg) 1-20 2.61 (1.44-4.70) <.001
>20








LVDDn <1.7 13.508 (6.796-26.847) <.001
≥1.7
LVSDn <1.2 4.744 (0.548-41.049) .22
≥1.2
FS (%) <40 0.303 (0.176-0.522) <.001
≥40
E max (m/s) <1.2 26.28 (13.44-51.41) <.001
≥1.2
PH No 2.977 (1.768-5.011) <.001
Yes





B1 + B2 59.99 (25.55-140.89) <.001
C + D
Abbreviations: ACVIM, American College of Veterinary Internal Medicine;
BW, body weight; CT, cardiac treatment; E max, mitral valve maximal E
wave velocity; FS, Fractional shortening; LA, left atrial diameter; LA/Ao,
left atrial diameter to aortic diameter; LVDDn, left ventricular diastolic
diameter normalized to body weight; LVSDn, left ventricular systolic diam-
eter normalized to body weight; MT, mixed treatment; NT, no treatment;
OT, other treatments; PH, pulmonary hypertension.
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disease. Supplemenatry Appendix shows the complete list of the vari-
ous drugs administered to dogs belonging to each treatment group.
Most of the dogs were crossbreds (851 dogs, 38.8%), and Miniature
and Toy Poodle (280 dogs, 12.8%), Miniature Pinscher (130 dogs,
5.9%), Dachshund (115 dogs, 5.2%), Lhasa Apso (106 dogs, 4.8%),
Yorkshire terrier (74 dogs, 3.4%), Cocker spaniel (70 dogs, 3.2%), and
Cavalier King Charles Spaniel (51 dogs, 2.3%) were the most com-
monly represented pure breeds. There were 1159 (52.8%) females.
The mean age was 136 months (SD = 36 months) and the mean BW
was 10.9 kg (SD = 8.5 kg).
Atrial fibrillation was diagnosed in 59 dogs with a prevalence of
2.7%. Twenty of these cases (33.9%) were diagnoses by an ECG trac-
ing obtained during the echocardiographic examination. Table 1 pre-
sents a comparison of clinical and echocardiographic variables
between dogs with AF and those without AF. In dogs with AF, the
percentage of crossbred dogs, male dogs, animals with PH, dogs with
decompensated HF, and dogs receiving CT was significantly higher
when compared to that of purebred dogs (P = .002), female dogs
(P < .001), dogs without PH (P < .001), dogs with compensated HF
(P < .001), and dogs receiving NT, MT, or OT (P < .001, P = .007, and
P < .001), respectively. Among the continuous variables, dogs with AF
had significantly increased mean BW, heart rate, LA, Ao, LA/Ao,
LVDDn, LVDSDn, and E max (P < .001 for all comparisons), and signif-
icantly decreased mean FS (P < .001) compared to dogs without AF,
whereas mean age was not different (P = .69).
Table 2 presents the results of the ROC curve analyses. The LA
(AUC = 0.979; 95% CI, 0.972-0.984) and LA/Ao (AUC = 0.931; 95%
CI, 0.920-0.941) had high accuracy to predict development of AF at
the cut offs >3.45 cm and >1.8, respectively. Both echocardio-
graphic indices had very high sensitivity (98.3% for both variables)
and high specificity (89.8% and 78.5% for LA and LA/Ao, respec-
tively) to predict the presence of AF. In particular, LA > 3.45 cm had
a PPV of 20.7% and NPV of 99.9% to predict development of
AF. The BW, LVDDn, LVSDn, and E max were only moderately
accurate to predict development of AF (AUC = 0.735; 95% CI,
0.716-0.754; 0.854, 0.796-0.912; 0.875, 0.821-0.929; 0.900,
0.887-0.912, respectively).
3.2 | Univariate and multivariable analysis
Univariate logistic regression showed that developing AF was posi-
tively correlated with mixed breeds (P = .002), male sex, BW ≥20 kg,
LA ≥3.45 cm, LA/Ao ≥1.6, LVDDn ≥1.7, E max ≥1.2 m/s, FS < 40%,
presence of PH, and ACVIM stage C + D (P < .001 for all variables;
Table 3).
Two final multivariable models were built including only signifi-
cant predictors and accounting for multicollinearity (Table 4). In
model 1, increased LA/Ao was confirmed as a strong risk factor for
developing AF (OR = 14.011; 95% CI, 7.463-26.304; P < .001)
followed by E max and BW (OR = 2.204 and 1.094; 95% CI,
1.192-4.076 and 1.058-1.130; P = .003 and P < .001, respectively).
Decreased FS also was associated with the risk of developing AF
(OR = 0.899; 95% CI, 0.865-0.934; P < .001). Model 2 showed that
increased LA and decompensated ACVIM stage are risk factors for
developing AF (OR = 5.280 and 4.922; 95% CI, 3.377-8.092 and
1.481-16.353; P < .001 and P = .009, respectively) and confirmed the
effect of decreased FS (OR = 0.919; 95% CI, 0.881-0.959; P < .001).
4 | DISCUSSION
The main results of our study were that development of AF is uncom-
monly associated with MMVD in dogs, accounting for 2.7% of cases.
Increased BW, LA, LA/Ao, and E max, and decreased FS as well as
decompensated stage of HF were associated with a higher risk for
developing AF in these dogs.
A previous epidemiological study conducted from 1969 to 2007
using the Veterinary Medical Data Base that included 26 colleges of
veterinary medicine in the United States found an increase of AF diag-
nosis in dogs over the study period ranging from 5.07 to 23.31 per
10 000 canine admission without any information regarding underly-
ing cardiac diseases.11 Large differences also were found according to
breed and associated BW because the prevalence of AF was 5.84%
and 0.04% in Irish Wolfhounds and Miniature Poodles, respectively.11
On the other hand, some studies specifically evaluated cardiac rhythm
TABLE 4 Results of the multivariable
logistic regression analysis for the risks
for developing atrial fibrillation in 2194
dogs with myxomatous mitral valve
disease
Predictors Odds ratio Lower 95% CI Upper 95% CI P value
Model 1
LA/Ao 14.011 7.463 26.304 <.001
E-max 2.204 1.192 4.076 .003
BW 1.094 1.058 1.130 <.001
FS 0.899 0.865 0.934 <.001
Model 2
LA 5.280 3.377 8.092 <.001
ACVIM stage C + D 4.922 1.481 16.353 .009
FS 0.919 0.881 0.959 <.001
Abbreviations: ACVIM, American College of Veterinary Internal Medicine; BW, body weight; E max,
mitral valve maximal E wave velocity; FS, fractional shortening; LA, left atrial diameter; LA/Ao, left atrial
diameter to aortic diameter.
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in dogs with MMVD. In 1 study, a longitudinal evaluation using stan-
dard ECG of 257 dogs found AF in 1.6% of them.18 Three other stud-
ies evaluated cardiac rhythm using standard ECG or Holter monitoring
or both in 36 dogs with MMVD of different stages, 43 dogs with
advanced MMVD with or without syncope, and 90 dogs with com-
pensated and decompensated MMVD.19-21 The presence of AF was
only found in 4 dogs (11.1%) of the former study, all of them in symp-
tomatic stages of the disease.19 Furthermore, in a study that com-
pared clinical findings in dogs with MMVD, including 58 German
Shepherds dogs and 49 small breed dogs (ie, BW < 15 kg), AF was
more prevalent in the former group when compared to latter dogs.22
Our study included a large group of dogs of different breeds, repre-
sentative of the entire population of dogs affected by MMVD regard-
ing either the signalment, because small breed dogs with advanced
age were overrepresented, or different disease stage and complica-
tions (eg, percentage of dogs with Doppler-derived diagnosis of
PH).8-10,16,23 The prevalence rate of 2.7% found in our study suggests
that AF is an uncommon complication of MMVD. Precise epidemio-
logical data seldom are available in the veterinary medical literature. In
addition to the direct useful information it conveys, knowledge of
prevalence rates of a given disease allows calculation of the PPV and
NPV of a diagnostic test or clinical variable. These predictive values
are more intuitive compared to the more commonly reported sensitiv-
ity and sensibility and are clinically very useful, as discussed below.24
Dogs with MMVD that developed AF had many differences in
clinical and echocardiographic variables compared to dogs without
AF. In particular, AF was more prevalent in crossbred, male dogs with
higher BW. Interestingly, age was similar in both groups of dogs (ie,
mean age > 11 years for both groups), which represents an important
difference when compared to humans where advanced age is a risk
factor for developing AF.1,2,5-7 Regarding echocardiographic variables,
dogs with AF had significantly increased LAE (ie, significant increases
of both LA and LA/Ao), LV dimension (both in systole and diastole),
and E max that represent an indirect index of increased left atrial
pressure,25 and significantly decreased FS. Unsurprisingly, AF was
found in a significantly higher percentage of dogs with
decompensated HF as well as in those with PH likely because these
changes are associated with a more advanced stage of
MMVD.9,10,17,25-27 Regarding evaluation of the diagnostic accuracy
for the above-mentioned continuous variables to predict development
of AF, BW, LVDDn, LVSDn, FS, and E max were only moderately
accurate, but LA and LA/Ao had high accuracy to predict development
of AF at the cut-offs of 3.45 cm and 1.8, respectively. In particular,
these 2 variables had excellent sensitivity (ie, 98.3% for both variables)
and high specificity (ie, 89.8% and 78.5%, respectively). However,
because of the observed low prevalence rates of AF in dogs with
MMVD, only LA reached a clinically useful PPV of 20.7%. This obser-
vation means that among dogs with MMVD that have LA > 3.45 cm,
it can be predicted that only 1 in 5 actually will develop AF.
Univariate analysis showed that crossbred, male dogs with
increased BW, LA, LA/Ao, LVDDn, and E max, decreased FS and with
PH and decompensated HF had increased risk of developing
AF. However, after the multivariable analyses, only the following
variables remained significantly associated with increased risk of
developing AF: increased BW, LA/Ao, LA, and E max, decreased FS,
and decompensated HF. These findings suggest that left atrial remo-
deling, characterized by both LAE and increased LA pressure, is a
major risk factor for developing AF in dogs with MMVD. In particular,
per each cm and an increment unit of LA and LA/Ao, there is a 5- and
14-fold increase in risk of developing AF, respectively. Similarly, for
each 1 m/s increase in E max, there is a 2-fold increased risk of devel-
oping AF. Body weight and decompensated HF are additional risk fac-
tors, meaning that for each kilogram of increased BW there is a 9%
increased risk, and dogs with ACVIM stages C and D have 5-fold
increased risk of developing AF. Conversely, for each 1% decrease of
FS, there is an 8% to 10% increased risk of developing AF. Many fac-
tors can be responsible for decreased FS in dogs with MMVD with or
without AF including higher BW, advanced stage of disease, loss of
the atrial component of LV filling, and tachycardia-induced
cardiomyopathy.12,22,28-30
Atrial structural, electrical, ionic, and functional remodeling
changes are considered the fundamental pathophysiological mecha-
nisms underlying AF in humans.31,32 In particular, left atrial structural
remodeling refers to adaptive or maladaptive changes in cardiac archi-
tecture that occur at the macro- and microscopic levels.31,32 The hall-
mark of macroscopic change is atrial dilatation, whereas fibrosis is the
most important microscopic change.31,32 In our study, the observed
association of increased LA and LA/Ao as well as increased E max
emphasizes the importance of left atrial remodeling as a risk factor for
developing AF in dogs with MMVD. Body weight was an additional
risk factor for developing AF in dogs, as compared with humans in
whom obesity and increased body mass index but not BW were risk
factors identified for developing AF.33 This difference between
humans and dogs can be easily explained by the large breed-
associated variability in the BW of dogs. Furthermore, BW also has an
effect on LAE. Because absolute left atrial dimension depends on BW
and severity of cardiac disease leading to LAE, not surprisingly LA had
the highest diagnostic accuracy and PPV to predict AF, and also com-
pared to the LA/Ao, which represents only a relative index of LAE.
Atrial fibrosis is 1 of the most important abnormalities contributing to
the development of AF in humans.34 Potential mediators known to
promote fibrosis in the atrium include pressure and volume overload,
aging, atrial stretch, inflammation, and oxidative stress.34 As atrial
myopathy progresses, it can lead to atrial dysfunction.34 Few studies
have investigated the microscopic changes of atrial myocytes in dogs
with MMVD or AF or both.35-37 In dogs with MMVD, the observed
changes included myocardial fatty replacement, immune cell infiltra-
tion, and interstitial fibrosis,35,36 whereas atrial histological changes in
dogs with AF were investigated mainly in animals with experimentally
induced arrhythmias.37 Evaluation of left atrial function recently has
been investigated in dogs with MMVD using speckle-tracking echo-
cardiography, and the results suggested the presence of left atrial dys-
function in more advanced stages of the disease.38-42 Furthermore, in
addition to absolute cardiac diameters, evaluation of LA function with
speckle-tracking echocardiography can be useful to predict develop-
ment of AF in dogs with MMVD.43
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Decompensated HF is a risk factor for AF in dogs with an OR
(4.9) similar to that observed in humans (4.5-5.9) in the classical Fra-
mingham heart study.44 Heart failure and AF are linked by similar risk
factors in humans and share a common pathophysiology. Thus, it is
widely accepted that HF and AF can cause and exacerbate each other
through mechanisms such as structural cardiac remodeling, activation
of neuro-hormonal mechanisms, and rate-related impairment of LV
function.44 Our results and those of another recent study suggest that
the same relationship between AF and HF also could be present in
dogs.29 However, the precise cause-effect relationship between HF
and AF remain elusive in our study as well as in studies of humans,45
because the temporal relationship of each condition could not be
determined. In addition, the prevalence of AF in HF is known to
increase with increased severity of pump failure in humans.46 Evalua-
tion of the systolic function is challenging in dogs with MMVD and
was not specifically addressed in our study. However, the observed
risk factor of decreased FS suggests that a similar pathophysiological
mechanism also might be present in dogs, but results of FS measure-
ments in subjects with MMVD can be misleading.28
Our study had some limitations because of its retrospective
design. The cardiac rhythm evaluation relied either on ECG recording
using a dedicated machine, the reference method for cardiac rhythm
evaluation, or using a good quality ECG recording during echocardio-
graphic examination. This latter represents a less reliable method of
accurate cardiac rhythm analysis and approximately one-third of AF
cases were diagnosed using echocardiography. However, because the
aim of our study was to identify dogs with AF compared to dogs with
any other cardiac rhythm, we propose that AF has specific ECG char-
acteristics (ie, irregularly irregular cardiac rhythm with narrow QRS
complexes and isoelectric trace without recognizable P wave) and
modifications of cardiac function (eg, absence of the A wave during
trans-mitral Doppler interrogation) that are easily recognizable during
echocardiographic examinations. Evaluation of the left atrial dimen-
sion was based on linear echocardiographic measurements whereas
other more accurate methods of left atrial size measurements, such as
an estimation of left atrial volume using the Simpson disk method or
use of 3D echocardiography,47,48 were not performed. However,
measurement of the LA and calculation of LA/Ao are the more com-
monly employed echocardiographic methods of evaluating left atrial
size in a clinical setting. Only a limited number of clinical variables
were retrieved, and therefore we could not evaluate the effect of
some risk factors for developing AF in humans such as obesity, sys-
temic hypertension, and other comorbidities (eg, diabetes mellitus,
chronic kidney disease).1,2 However, systemic hypertension does not
seem to be an important issue in dogs with MMVD, even in the most
advanced stage of the disease.49 In addition, the number of available
echocardiographic variables was limited. Although the presence of
other cardiac diseases was an exclusion criterion, we could not
completely rule out the presence of subtle cardiac diseases (eg,
arrhythmogenic cardiomyopathy) in the early phase of their progres-
sion. No thorough information regarding specific concomitant extra-
cardiac diseases could be retrieved, but the administration of OT, a
surrogate of other relevant concomitant diseases, neither showed any
statistical difference in dogs with AF nor represented a risk factor of
AF development. Finally, AF is not a unique entity but can be classi-
fied as paroxysmal, persistent, long-standing persistent, and perma-
nent according to the duration of arrhythmic episodes.1,2 This scheme
of classification described in humans is seldom used in veterinary
medicine, and no attempt was made in our study to better define the
specific type of AF.
5 | CONCLUSIONS
In conclusion, AF is uncommonly associated with AF in dogs with
MMVD. Left atrial remodeling associated with LAE and increased left
atrial pressure, increased BW, decreased FS, and decompensated HF
are risk factors for developing AF in dogs. Conversely, increased age,
a demonstrated risk factor of developing AF in humans, does not
appear to play a similar role in dogs. Future studies investigating the
complex pathophysiological mechanisms of this arrhythmia should
include further evaluation of atrial pathology and dysfunction in dogs
with AF.
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